Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Vaccine for follicular lymphoma


A team of researchers has demonstrated the clinical efficacy and benefits of a vaccine for a type of blood cancer, follicular lymphoma, amongst first time relapse patients. Specialists from two University of Navarre centres – the University Hospital and the Research Centre for Applied Medicine (CIMA) - have worked jointly since 2001 on the research.

According to Dr. Maurizio Bendandi, the team leader, it is the first time that a vaccine against a type of cancer has been able to change the history of the illness.

More than 5000 persons in Spain diagnosed with this tumour each year

In Spain more than 5000 persons over 40 are annually diagnosed with this type of cancer. Follicular lymphoma is a tumour of the lymphatic system the cells of which present a surface protein – in fact, an immunoglobuline - that can be used as a target. The vaccine, known as idiotypical, is produced from this protein and its aim is to provoke a reaction from the immune system of the patient. Normally the patient does not react against the protein of the tumour given that, as it is a known element, its immune system does not combat it. By means of laboratory techniques we have managed to adhere to the target protein another protein called KLH, obtained from a mollusc. In this way we managed to get the tumoural protein also to be recognised as foreign.

In the case of follicular lymphoma, this protein is a specific tumour antigen. It is postulated that there are also antigens in other tumours but, for the moment, none has been identified solely and exclusively in the tumour cells and, thus, a vaccine against these would also be damaging to healthy tissues.

Stanford University developed an idiotypical vaccine in the seventies in animals and applied it to humans 15 years ago. In 1992 its biological efficacy was tested: it is capable of stimulating the human immune system. In 1999 Dr. Bendandi and other scientists at the US National Cancer Institute demonstrated that this biological efficacy was also clinical. According to the University of Navarre researcher, the vaccine-stimulated immune system itself is capable of killing some tumour cells that had resisted quimiotherapy. It remains to be demonstrated that this result provides a real benefit to the patient.

Better response hoped for than with quimiotherapy only

With the research work carried out at CIMA and the University Hospital it is known that 50% of the patients treated with quimiotherapy relapse within13 months. Moreover, the duration of the response time tends to be shorter between relapses than between the previous ones.

Our research involved 25 patients over the last four and a half years. Of these, 4 patients did not respond to the vaccine and relapsed in the expected time, with another 3 the study of their illness is yet to finish and 18 responded satisfactorily. None of these 18 has relapsed over the two years vaccination.

Research in California, Texas and Navarre

This is the first study of this kind or design to investigate the efficacy of the vaccine in patients suffering relapse, although other clinical trials are being undertaken at two centres in the United States.

The vaccine, administered subcutaneously, is especially useful as a complement to quimiotherapy. There have been attempts to apply the vaccine as a first treatment but the results have not been satisfactory.

In general terms, the procedure followed with patients at the University Hospital was to give them conventional quimiotherapy for 6 months in order to reduce the size of the tumour as much as possible. This was followed by a rest period of between 3 and 6 months in order to reconstitute the immune system. Finally, the vaccine was innoculated every month for three or four months, whereupon the frequency of this dosage was gradually reduced.

Irati Kortabitarte | alfa
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>